8-K: Current report filing
Published on March 19, 2008
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.20549
|
|
FORM
8-K
|
|
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
|
Date
of Report (Date of earliest event reported): March
17, 2008
|
|
ACCESS PHARMACEUTICALS,
INC.
|
|
|
|
(Exact
name of registrant as specified in its charter)
|
|
Delaware
|
0-9314
|
83-0221517
|
|
|
|
|
|
(State
or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
|
2600 Stemmons Freeway, Suite
176
Dallas, Texas |
|
75207
|
|
|
|
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant's telephone number, including
area code:
|
(214) 905-5100
|
|
|
|
|
|
|
|
|
|
|
(Former
name or former address, if changed since last report)
|
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
|
|
/ /
|
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
|
|
/ /
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
/ /
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
/ /
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM 1.01
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
ITEM
5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL
OFFICERS; ELECTION OF
DIRECTORS;
APPOINTMENT OF PRINCIPAL
OFFICERS.
As
previously reported, Stephen R. Seiler, our former President and Chief Executive
Officer resigned on December 16, 2007, as President and Chief Executive Officer.
He resigned his employment as of December 31, 2007.
A separation agreement and general release was signed on March 17,
2008. Pursuant to the agreement, Mr. Seiler is entitled to vesting of options of
100,000 shares of common stock of the Company. Such options are exercisable on
or before March 12, 2010. Mr. Seiler is also entitled the continuation
of his healthcare benefits for twelve months. Mr. Seiler also agreed to provide
consulting services to the Company for a period up to six months on an as
requested basis by the Company, at a per diem rate equal to his daily salary in
effect on his resignation date. Both Mr. Seiler and the Company agreed to a
release.
As previously reported, Jeffrey B. Davis is now the Company's Chief Executive Officer.
|
SIGNATURES
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ACCESS PHARMACEUTICALS, INC.
(Registrant)
|
|
|
|
|
By:
|
/s/ Stephen B. Thompson
|
|
|
|
|
|
|
|
|
Stephen B. Thompson
|
|
|
|
Vice President, Chief Financial
Officer
|
|
Date: March 19, 2008
|
|